Pharming Group (PHAR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.06
- Surprise
- -96.8%
- Revenue (period 2026-06-30)
- $90.2M
- Score today
- 5.6/10
Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAR Hold at 5.6/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -96.8% surprise compares with a -1653.7% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive news sentiment (+0.67)
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
- Below 200-MA, MA slope -4.2%/30d (confirmed downtrend)
- DATA_ISSUE: analyst_target_implausible (raw $34.35 vs price $10.44 — ratio 3.3×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.44
- Price target
- $11.72
- Stop
- $10.05
- Upside to target
- +12.3%
The stock trades at 82.8× trailing but 35.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
PHAR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $762.3M
- P/E (fwd)
- 35.1
- P/E (ttm)
- 82.8
- 52-week range
- $9.62–$21.34
- Off 52-week high
- 51.1%
- RSI (14)
- 38
- Volume vs avg
- 1.06×
- Score today
- 5.6/10